Thus, the tumor uptake in the Entresto®-treated animals was found to be significantly decreased in comparison to block 1 (single NTS1R-block; from 11.57 ± 1.92%IA to 7.28 ± 1.00%IA/g; p < 0.0001), block 2 (single GRPR-block; from 11.57 ± 1.92%IA to 3.57 ± 0.44%IA/g; p < 0.0001) and block 3 (double NTS1R/GRPR-block; from 11.57 ± 1.92%IA to 2.05 ± 0.53%IA/g; p < 0.0001). This evidence concerns the gene GRPR and neoplasm.